Form 4: IRADIMED CFO John Glenn Reports Routine RSU Vesting and Tax-Related Share Sale

IRADIMED Corporation's Chief Financial Officer, John Glenn, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• John Glenn, the Chief Financial Officer of IRADIMED Corporation (IRMD), reported transactions involving the company's common stock.
• On June 20, 2025, Mr. Glenn acquired 5,796 shares of common stock upon the vesting of restricted stock units (RSUs) on a one-for-one basis.
• These RSUs were originally granted on June 20, 2022, under Iradimed Corporation's 2014 Equity Incentive Plan, with vesting occurring in four equal annual installments beginning June 20, 2023.
• Concurrently, Mr. Glenn disposed of 1,412 shares of common stock at a price of $58.24 per share to satisfy tax withholding obligations related to the RSU vesting.
• Following these transactions, Mr. Glenn's direct beneficial ownership of common stock stands at 13,151 shares.

Sentiment

Score: 5

Explanation: The document reports a routine, pre-scheduled insider transaction related to equity compensation. There are no indications of positive or negative sentiment beyond the standard nature of such a filing.

Positives

• The vesting of 5,796 restricted stock units indicates the realization of equity compensation for the Chief Financial Officer, aligning management's interests with shareholder value over time.
• The transaction is a routine, pre-scheduled event under the company's 2014 Equity Incentive Plan, reflecting a standard compensation structure.

Negatives

• The disposition of 1,412 shares, although for tax purposes, represents a reduction in the Chief Financial Officer's direct ownership of the company's common stock.

Future Outlook

This Form 4 filing primarily reports past transactions related to equity compensation and does not contain forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Industry Context

This filing is a routine insider transaction report, common across all industries for publicly traded companies. It reflects the standard practice of equity-based compensation for executives and the associated tax implications, rather than specific industry trends or competitive dynamics.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a change in company strategy or financial health. The sale of shares for tax purposes is a common occurrence and typically has minimal impact on the broader share price.
• Employees: The report highlights the company's equity incentive plan, which can be a component of employee compensation, potentially impacting morale and retention.

Key Dates

Keywords

IRADIMED CORP, IRMD, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Equity Compensation, Chief Financial Officer, Stock Sale, Tax Withholding